The most recent announcement from the National Pharmaceutical Pricing Authority (NPPA), the central regulatory agency overseeing drug prices in India, suggests a significant xxx-xxx decrease in the prices of at least twelve medications. These include commonly used treatments for cardiac diseases, inflammation, duodenal ulcers, and bacterial infections. This reduction, noted as the highest in recent memory, comes as part of the NPPA&#xx;s ongoing efforts to regulate pharmaceutical costs.
The revised maximum retail prices for certain medications have been announced, reflecting a positive change for consumers. A strip of xx Bilastine and Montelukast tablets, addressing various allergic conditions such as inflammation, itching, and rashes, will now be available at a maximum retail price of Rs xxx, down from the previous Rs xxx. Additionally, a combination drug containing aceclofenac, paracetamol, and serratipetid, aimed at alleviating pain and swelling in conditions like muscle pain, joint pain, and post-operative pain,...
